Cerebral hemorrhage in acute ischemic stroke（ AIS） patients is a serious complication after thrombolytic therapy using recombinant tissue plasminogen activator（ rt-PA）. The rt-PA increases the risk of bleeding while treating local thrombolysis， which potentially leads to cerebral hemorrhagic transformation（ CHT）. This process is related to the gene polymorphism and physiological differences of plasminogen activator inhibitor 1（ PAI1） and thrombin-activatable fibrinolysis inhibitor（ TAFI）. Body temperature， age， brain CT or MRI imaging， blood pressure and blood sugar levels are factors that can affect the likelihood of cerebral hemorrhage caused by rt-PA thrombolytic therapy while treating AIS. In rt-PA thrombolytic therapy， it is of great clinical importance to adopt predictive monitoring and purposeful nursing for AIS patients with different physiological conditions and clinical characteristics.